| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
POET's optical technology R&D and dilution history have created market skepticism that has compressed valuation. If optical tech adoption scales as hoped, today's price is tiny relative to the potential upside.
RZLV is mislabeled as pure hype despite real sales, a Microsoft partnership, and existing clients. Currently valued too pessimistically relative to its fundamentals, offering significant upside without requiring perfection.
GRRR is priced to fail despite having real government and enterprise customers. If backlog converts to steady revenue as expected, the current market cap is too low and the stock can 5-10x as the market reprices the company.
End of results.